Superior execution and lower RM costs drive earnings

Company

06 Aug 2024 | 5 Min Read

GSK Pharma's 1QFY25 results update and financials

Estimate, TP, and rating change

Sales, EBITDA, and Adj. PAT growth

Valuations and shareholding pattern

Strong demand in specialty portfolio

Plans for operational efficiency and new products

Reiterate Neutral with 9% earnings CAGR.